Loading...
VERV logo

Verve Therapeutics, Inc.NasdaqGS:VERV Stok Raporu

Piyasa Değeri US$991.5m
Hisse Fiyatı
n/a
1Y48.8%
7D1.6%
1D0.3%
Portföy Değeri
​
Görünüm

Verve Therapeutics, Inc.

NasdaqGS:VERV Stok Raporu

Piyasa değeri: US$991.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Verve Therapeutics (VERV) Hisse Özeti

Klinik aşamada bir şirket olan Verve Therapeutics, Inc. Amerika Birleşik Devletleri'nde kardiyovasküler hastalıkları tedavi etmek için hastalara yönelik gen düzenleme ilaçları geliştirmektedir. Daha fazla detay

Risk Analizi

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 15.7% oranında düşmesi öngörülüyor

Son 3 ayda hisse senedi fiyatı US piyasasına kıyasla oldukça dalgalı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor


VERV Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW440,641 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
440,641 investors already sharing narratives
View all narratives

Verve Therapeutics, Inc. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Verve Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse FiyatıUS$11.13
52 Haftanın En Yüksek SeviyesiUS$11.41
52 Haftanın En Düşük SeviyesiUS$2.86
Beta2.24
1 Aylık Değişim-0.36%
3 Aylık Değişim93.23%
1 Yıllık Değişim48.80%
3 Yıllık Değişim-59.60%
5 Yıllık Değişimn/a
Halka arzdan bu yana değişim-65.13%

Son Haberler & Güncellemeler

Seeking Alpha • Jun 17

Verve Therapeutics' Lifeline: Eli Lilly's $1.3 Billion Bet On Cardiovascular Gene Therapy (Upgrade)

Summary Eli Lilly's $1.3B offer for Verve Therapeutics is a lifeline, providing a 70%+ premium and a solid exit for Verve investors. VERV struggled as a standalone due to tough gene therapy commercialization and competition from established cardiovascular treatments like statins and PCSK9 inhibitors. For LLY, the acquisition diversifies its pipeline and positions it for future innovation in chronic disease, despite high risk and uncertain payoff. The deal is mutually beneficial: Verve gets a strong exit, while Eli Lilly makes a speculative, forward-looking bet with its abundant cash reserves. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Jun 17

Verve Therapeutics' Lifeline: Eli Lilly's $1.3 Billion Bet On Cardiovascular Gene Therapy (Upgrade)

Summary Eli Lilly's $1.3B offer for Verve Therapeutics is a lifeline, providing a 70%+ premium and a solid exit for Verve investors. VERV struggled as a standalone due to tough gene therapy commercialization and competition from established cardiovascular treatments like statins and PCSK9 inhibitors. For LLY, the acquisition diversifies its pipeline and positions it for future innovation in chronic disease, despite high risk and uncertain payoff. The deal is mutually beneficial: Verve gets a strong exit, while Eli Lilly makes a speculative, forward-looking bet with its abundant cash reserves. Read the full article on Seeking Alpha
Analiz Makalesi • May 28

Verve Therapeutics, Inc. (NASDAQ:VERV) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Unfortunately for some shareholders, the Verve Therapeutics, Inc. ( NASDAQ:VERV ) share price has dived 26% in the last...
Analiz Makalesi • May 19

News Flash: Analysts Just Made An Incredible Upgrade To Their Verve Therapeutics, Inc. (NASDAQ:VERV) Forecasts

Verve Therapeutics, Inc. ( NASDAQ:VERV ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Apr 16

Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy'

Summary VERV’s VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Also, LLY may opt into VERVE-102’s development later this year, which would help VERV by covering one-third of the R&D costs. Similarly, VERV’s pipeline includes VERVE-201 for HoFH and refractory hypercholesterolemia, as well as VERVE-301 in collaboration with Lilly. And from a valuation perspective, the shares are cheaper than the first time I covered it. All while making great progress with its pipeline. So, ultimately, I think VERV remains a high-risk, long-term play in gene editing. But its risk-reward profile now seems to justify a “Buy” rating. Read the full article on Seeking Alpha
Seeking Alpha • Mar 25

Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts

Summary Company received FDA IND clearance for VERVE-102 to treat HeFH, adding new trial sites in the United States. The switch to the Gal-NAc LNP delivery system aims to improve safety, avoiding clinical abnormalities observed with VERVE-101. Key upcoming catalysts include initial phase 1b Heart-2 data in Q2 2025, final dose-escalation data, and potential Eli Lilly opt-in for PCSK9 inhibitor program in the 2nd half of 2025. Atherosclerotic Cardiovascular Disease, in the 7 Major Markets, is expected to reach $30.6 billion by 2035. Read the full article on Seeking Alpha
Seeking Alpha • Feb 28

Verve Therapeutics: Key Data Catalysts, Major Share Price Volatility In Play In Q2

Summary Verve Therapeutics' stock remains a "Buy" despite recent setbacks, including the retirement of its Chief Medical Officer and the termination of a collaboration with Vertex. Verve's gene-editing programs aim to transform cardiovascular disease treatment by permanently lowering cholesterol through a one-time intravenous infusion, offering significant therapeutic and commercial potential. The upcoming data readout for Verve-102 in 2025 is crucial; success could attract Eli Lilly's partnership, while failure may question the entire base editing approach. Despite leadership changes and challenges, Verve's innovative approach and potential for groundbreaking treatments justify a high-risk, high-reward investment strategy. Read the full article on Seeking Alpha
Analiz Makalesi • Dec 08

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Aug 30

Verve Therapeutics: An In Vivo Gene Editing 'Moon Shot' For Your Portfolio

Summary Verve Therapeutics aims to revolutionize cardiovascular disease treatment with single-course gene editing, despite facing significant challenges and setbacks in clinical trials. The company's lead assets, VERVE-101 and VERVE-102, target the PCSK9 gene to lower LDL-C levels, but safety issues have hindered progress. Verve-102, using a different delivery technology, is now the focus, with initial data expected in 1H25, presenting a crucial milestone for investors. Partnerships with Eli Lilly, Beam Therapeutics, and Vertex offer potential financial support and validation, but Verve remains a high-risk, high-reward investment. Read the full article on Seeking Alpha
Analiz Makalesi • Aug 10

Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78

As you might know, Verve Therapeutics, Inc. ( NASDAQ:VERV ) just kicked off its latest second-quarter results with some...
Analiz Makalesi • Jul 12

We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Jun 13

Why Verve Therapeutics Deserves A Spot On Your Watchlist

Summary Verve Therapeutics focuses on gene editing technology for one-dose therapies to reduce lipid levels related to ASCVD. VERV's pipeline includes therapies targeting genes like PCSK9, ANGPTL3, and LPA to lower ASCVD risk. Verve's leading programs, VERVE-101 and VERVE-102, target heterozygous familial hypercholesterolemia (HeFH), with VERVE-101 in clinical trials and VERVE-102 in the IND-enabling stage. Financially, Verve has a strong cash position, with $606.3 million in liquidity and a cash runway of approximately 3.5 years. VERV's research is in the early stages, making it a speculative investment, but it is worth adding to a watchlist as research progresses. Read the full article on Seeking Alpha
Analiz Makalesi • May 14

Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

Verve Therapeutics, Inc. ( NASDAQ:VERV ) shareholders will have a reason to smile today, with the analysts making...
Analiz Makalesi • May 12

The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts

As you might know, Verve Therapeutics, Inc. ( NASDAQ:VERV ) just kicked off its latest first-quarter results with some...
Seeking Alpha • Apr 03

Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause

Summary Enrollment paused in the Verve Therapeutics' phase 1b heart-1 study, using VERVE-101 for the treatment of patients with heterozygous familial hypercholesterolemia after a Grade 3 adverse event. Despite VERVE-101 setback, the ability to move forward with another PCSK9 inhibitor known as VERVE-102 where the phase 1b heart-2 study is expected to begin any day now in Q2 2024. VERVE-102 could be a major change in structure because it has two distinct features compared to its predecessor, which are a different ionizable lipid and the GalNAc delivery system. Partnership with Eli Lilly remains in place for now, despite VERVE-101 enrollment being paused. Read the full article on Seeking Alpha
Analiz Makalesi • Feb 28

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 13

Verve's Proof-Of-Concept Data Doesn't Inspire Confidence

Summary Verve Therapeutics aims to revolutionize cardiovascular disease treatment with gene therapy. Recent VERVE-101 data shows LDL-C reduction comparable to existing drugs but with serious adverse events in two patients, raising safety concerns. Verve's financials show a solid runway with ~$600 million in liquid assets after a recent capital infusion, but ongoing and future trials will demand substantial funding. Recommendation: Sell. Despite proof-of-concept and a one-time treatment appeal, safety concerns and competitive landscape challenge its long-term valuation. Read the full article on Seeking Alpha
Seeking Alpha • Jan 14

Vectoring In On Verve Therapeutics

Summary Verve Therapeutics aims to revolutionize treatment for cardiovascular disease through in vivo gene therapy using base editing technology. Their lead candidate, VERVE-101, has shown promising results in reducing LDL-C levels in preclinical studies. Verve has partnerships with Beam Therapeutics, Eli Lilly, and Vertex Pharmaceuticals, and analysts have a positive outlook on the company. A full investment analysis around Verve Therapeutics stock is presented in the paragraphs below. Read the full article on Seeking Alpha
Analiz Makalesi • Jun 07

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analiz Makalesi • Feb 24

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Nov 09

We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 20

Verve Therapeutics: Cathie Wood Adds To ARKK

Summary ARKG component added to flagship fund. Meaningful position would top 7% of outstanding shares. Company fits usual pattern with large losses and cash burn.

Hissedar Getirileri

VERVUS BiotechsUS Pazar
7D1.6%-5.2%-0.9%
1Y48.8%37.6%14.2%

Getiri vs. Endüstri: VERV geçen yıl % 37.6 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: VERV geçen yıl % 14.2 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is VERV's price volatile compared to industry and market?
VERV volatility
VERV Average Weekly Movement24.9%
Biotechs Industry Average Movement9.5%
Market Average Movement6.9%
10% most volatile stocks in US Market15.3%
10% least volatile stocks in US Market2.9%

İstikrarlı Hisse Senedi Fiyatı: VERV hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.

Zaman İçindeki Volatilite: VERV 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 18% dan 25% a yükseldi.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
2018274Sek Kathiresanwww.vervetx.com

Klinik aşamada bir şirket olan Verve Therapeutics, Inc. Amerika Birleşik Devletleri'nde kardiyovasküler hastalıkları tedavi etmek için hastalara yönelik gen düzenleme ilaçları geliştirmektedir. Şirketin ürün adayları arasında, heterozigot ailesel hiperkolesterolemi (HeFH) hastalarında kan PCSK9 proteini ve LDL-C seviyelerindeki değişikliklerin yanı sıra açık etiketli bir Faz 1b klinik çalışması olan Heart-1 çalışmasında değerlendirilmekte olan VERVE-101 yer almaktadır; HeFH ve/veya erken koroner arter hastalığı olan yetişkin hastalarda açık etiketli bir Faz 1b klinik çalışması olan Heart-2 çalışmasında değerlendirilmekte olan VERVE-102; ANGPTL3'ü hedef alan ve karaciğerdeki ANGPTL3 genini kalıcı olarak kapatan VERVE-201; ve kan Lp(a) seviyelerini düşürmek amacıyla karaciğerdeki LPA genini kalıcı olarak kapatmak için yeni bir in vivo gen düzenleme yaklaşımı kullanan bir geliştirme adayı olan VERVE-301. Beam Therapeutics Inc. ile bir işbirliği ve lisans anlaşması; Acuitas Therapeutics, Inc. ile bir geliştirme ve opsiyon anlaşması; Novartis Pharma AG; Eli Lilly and Company ile lipid teknolojisi lisans anlaşması ve The Broad Institute and the President and Fellows of Harvard College ile bir Cas9 lisans anlaşması bulunmaktadır.

Verve Therapeutics, Inc. Temel Bilgiler Özeti

Verve Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
VERV temel i̇stati̇sti̇kler
Piyasa değeriUS$991.46m
Kazançlar(TTM)-US$181.01m
Gelir(TTM)US$59.61m
16.7x
P/S Oranı
-5.5x
F/K Oranı

VERV aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
VERV gelir tablosu (TTM)
GelirUS$59.61m
Gelir MaliyetiUS$210.43m
Brüt Kâr-US$150.82m
Diğer GiderlerUS$30.19m
Kazançlar-US$181.01m

Son Raporlanan Kazançlar

Mar 31, 2025

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)-2.03
Brüt Marj-252.99%
Net Kâr Marjı-303.64%
Borç/Özkaynak Oranı0%

VERV uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2025/07/24 06:46
Gün Sonu Hisse Fiyatı2025/07/24 00:00
Kazançlar2025/03/31
Yıllık Kazançlar2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Verve Therapeutics, Inc. 3 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Andrea NewkirkGoldman Sachs
Mitchell KapoorH.C. Wainwright & Co.
Dae Gon HaStifel, Equities Research